Log in to search using one of your social media accounts:

 

RALOXIFENE (Raloxifene Hydrochloride) Tablet, Film Coated [Avera McKennan Hospital]
Updated Date: Apr 11, 2017 EST (Source: DailyMed Drug Label Updates)
Source: DailyMed Drug Label Updates - April 11, 2017 Category: Drugs & Pharmacology Source Type: news

RALOXIFENE HYDROCHLORIDE Tablet, Film Coated [Avera McKennan Hospital]
Updated Date: Apr 10, 2017 EST (Source: DailyMed Drug Label Updates)
Source: DailyMed Drug Label Updates - April 10, 2017 Category: Drugs & Pharmacology Source Type: news

EVISTA (Raloxifene Hydrochloride) Tablet [PD-Rx Pharmaceuticals, Inc.]
Updated Date: Feb 6, 2017 EST (Source: DailyMed Drug Label Updates)
Source: DailyMed Drug Label Updates - February 6, 2017 Category: Drugs & Pharmacology Source Type: news

RALOXIFENE HYDROCHLORIDE Tablet, Film Coated [ScieGen Pharmaceuticals Inc]
Updated Date: Dec 7, 2016 EST (Source: DailyMed Drug Label Updates)
Source: DailyMed Drug Label Updates - December 7, 2016 Category: Drugs & Pharmacology Source Type: news

RALOXIFENE HYDROCHLORIDE (Raloxifene) Tablet [American Health Packaging]
Updated Date: Dec 1, 2016 EST (Source: DailyMed Drug Label Updates)
Source: DailyMed Drug Label Updates - December 1, 2016 Category: Drugs & Pharmacology Source Type: news

RALOXIFENE HYDROCHLORIDE Tablet, Film Coated [Dr.Reddys Laboratories Inc]
Updated Date: Nov 25, 2016 EST (Source: DailyMed Drug Label Updates)
Source: DailyMed Drug Label Updates - November 25, 2016 Category: Drugs & Pharmacology Source Type: news

Evista (Raloxifene) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - October 3, 2016 Category: Drugs & Pharmacology Source Type: news

Evista (raloxifene)
Title: Evista (raloxifene)Category: MedicationsCreated: 7/23/1998 12:00:00 AMLast Editorial Review: 9/30/2016 12:00:00 AM (Source: MedicineNet Menopause General)
Source: MedicineNet Menopause General - September 30, 2016 Category: Primary Care Source Type: news

Evista Blunts Symptoms in Women With Schizophrenia
(MedPage Today) -- No safety issues in small study, but thromboembolic risk remains concern (Source: MedPage Today Psychiatry)
Source: MedPage Today Psychiatry - July 21, 2016 Category: Psychiatry Source Type: news

RALOXIFENE HYDROCHLORIDE Tablet, Film Coated [KAISER FOUNDATION HOSPITALS]
Updated Date: Jul 11, 2016 EST (Source: DailyMed Drug Label Updates)
Source: DailyMed Drug Label Updates - July 11, 2016 Category: Drugs & Pharmacology Source Type: news

RALOXIFENE HYDROCHLORIDE (Raloxifene) Tablet [Cipla USA Inc.]
Updated Date: Jun 29, 2016 EST (Source: DailyMed Drug Label Updates)
Source: DailyMed Drug Label Updates - June 29, 2016 Category: Drugs & Pharmacology Source Type: news

RALOXIFENE HYDROCHLORIDE Tablet, Film Coated [Amneal Pharmaceuticals Of New York, LLC]
Updated Date: May 27, 2016 EST (Source: DailyMed Drug Label Updates)
Source: DailyMed Drug Label Updates - May 27, 2016 Category: Drugs & Pharmacology Source Type: news

RALOXIFENE HYDROCHLORIDE Tablet, Film Coated [Teva Pharmaceuticals USA, Inc.]
Updated Date: Apr 19, 2016 EST (Source: DailyMed Drug Label Updates)
Source: DailyMed Drug Label Updates - April 19, 2016 Category: Drugs & Pharmacology Source Type: news

RALOXIFENE HYDROCHLORIDE Tablet, Film Coated [Glenmark Pharmaceuticals Inc., USA]
Updated Date: Mar 25, 2016 EST (Source: DailyMed Drug Label Updates)
Source: DailyMed Drug Label Updates - March 25, 2016 Category: Drugs & Pharmacology Source Type: news

VIDEO: Advice varies for chemoprevention, genetic testing in invasive breast cancer
MIAMI – The message from major trials evaluating tamoxifen, raloxifene, and aromatase inhibitors for chemoprevention of invasive breast cancer got clearer with data from extended follow-up coming in.... (Source: Family Practice News)
Source: Family Practice News - March 12, 2016 Category: Primary Care Source Type: news

Raloxifene in Postmenopausal SchizophreniaRaloxifene in Postmenopausal Schizophrenia
Raloxifene improves negative symptoms in postmenopausal women with schizophrenia on antipsychotic treatment, a new study in 70 patients shows. Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - December 16, 2015 Category: Consumer Health News Tags: Psychiatry News Source Type: news

RALOXIFENE HYDROCHLORIDE (Raloxifene Hydrochloride) Tablet [Avera McKennan Hospital]
Updated Date: Nov 23, 2015 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))
Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST) - November 23, 2015 Category: Drugs & Pharmacology Source Type: news

Raloxifene Fails to Affect Cognition in Alzheimer's Disease (CME/CE)
(MedPage Today) -- But subtle benefits can't be ruled out (Source: MedPage Today Geriatrics)
Source: MedPage Today Geriatrics - November 5, 2015 Category: Geriatrics Source Type: news

No Cognitive Benefit of Raloxifene in Women with Alzheimer's No Cognitive Benefit of Raloxifene in Women with Alzheimer's
The selective estrogen receptor modulator failed to improve cognition in a small study of women with AD, although the possibility of a small cognitive benefit can't be excluded, researchers say. Medscape Medical News (Source: Medscape Neurology and Neurosurgery Headlines)
Source: Medscape Neurology and Neurosurgery Headlines - November 5, 2015 Category: Neurology Tags: Neurology & Neurosurgery News Source Type: news

Hormone-Like Drug Doesn't Help Women With Alzheimer's: Study
Researchers find no benefits from raloxifene in those with mild to moderate dementia (Source: WebMD Health)
Source: WebMD Health - November 4, 2015 Category: Consumer Health News Source Type: news

The Estrogen Drug That Reduces Your Breast...
Evista (raloxifene) is a drug that has been used for treatment of osteoporosis in postmenopausal women. The FDA has also approved it for prevention of invasive breast cancer. Evista creates an estrogen blockade, which lowers the incidence of estrogen-sensitive breast cancer. Learn more about Evista - uses, side effects, and benefits. (Source: About.com Breast Cancer)
Source: About.com Breast Cancer - October 18, 2015 Category: Cancer & Oncology Authors: breastcancer.guide at about.com Tags: health Source Type: news

Comparison of the Effects of the Selective Estrogen Receptor Modulators Ospemifene, Raloxifene, and Tamoxifen on Breast Tissue in Ex Vivo Culture
Explant tissue culture provides a model for studying the direct effects of steroid hormones, their analogs, and novel hormonally active compounds on normal freshly isolated human breast tissues (HBTs). For this purpose, pre- and postmenopausal HBTs can be maintained in this culture system. The results demonstrate that the morphological integrity of HBT explants can be maintained in tissue culture up to 2 weeks and expression of differentiation markers, steroid hormone receptors, proliferation and apoptosis ratios can be evaluated as a response to hormonal stimulation. This chapter describes an ex vivo culture model that we...
Source: Springer protocols feed by Biochemistry - October 12, 2015 Category: Biochemistry Source Type: news

Detection of Endogenous Selective Estrogen Receptor Modulators such as 27-Hydroxycholesterol
The estrogen receptors (ERs) belong to the nuclear receptor superfamily, and as such act as ligand inducible transcription factors, mediating the effects of estrogens. However, their pharmacology is complex, having the ability to be differentially activated by ligands. Such ligands possess the ability to behave as either ER-agonists or ER-antagonists, depending on the cellular and tissue context, and have been termed Selective Estrogen Receptor Modulators (SERMs). Several SERMs have been identified with clinical relevance such as tamoxifen and raloxifene. Recently, 27-hydroxycholesterol has been characterized as the first ...
Source: Springer protocols feed by Biochemistry - October 11, 2015 Category: Biochemistry Source Type: news

RALOXIFENE HYDROCHLORIDE Tablet, Film Coated [Prasco Laboratories]
Updated Date: Sep 29, 2015 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))
Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST) - September 29, 2015 Category: Drugs & Pharmacology Source Type: news

RALOXIFENE HYDROCHLORIDE Tablet, Film Coated [Aurobindo Pharma Limited]
Updated Date: Sep 1, 2015 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))
Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST) - September 1, 2015 Category: Drugs & Pharmacology Source Type: news

Aurobindo Pharma gets US FDA nod for generic osteoporosis drug
Aurobindo Pharma has received approval from the US FDA to manufacture and market its generic version of Eli Lilly's Evista tablets used to treat and prevent osteoporosis. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - August 29, 2015 Category: Pharmaceuticals Source Type: news

RALOXIFENE (Raloxifene Hydrochloride) Tablet, Film Coated [Actavis Pharma, Inc.]
Updated Date: Jun 19, 2015 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))
Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST) - June 19, 2015 Category: Drugs & Pharmacology Source Type: news

Some 'Benign' Breast Masses Pose Greater Cancer Risk Than We Thought
By Gene Emery (Reuters Health) - A type of "benign" mass found in the breast tissue of about 100,000 U.S. women each year poses a greater risk of cancer than previously thought, according to a new review. The mass is classified as atypical hyperplasia, or atypia. Most women who have it - and one out of 10 women who have a breast biopsy do - are usually told that their test result was benign, even though their cells seemed to be exhibiting some early characteristics of a tumor. Doctors may tell those women that they face an above-average risk of cancer so they need to be followed more closely,...
Source: Healthy Living - The Huffington Post - December 31, 2014 Category: Consumer Health News Source Type: news

RALOXIFENE HYDROCHLORIDE Tablet [American Health Packaging]
Updated Date: Nov 21, 2014 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))
Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST) - November 21, 2014 Category: Drugs & Pharmacology Source Type: news

RALOXIFENE HYDROCHLORIDE Tablet, Film Coated [Exelan Pharmaceuticals, Inc.]
Updated Date: Nov 14, 2014 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))
Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST) - November 14, 2014 Category: Drugs & Pharmacology Source Type: news

RALOXIFENE HYDROCHLORIDE (Raloxifene Hydrochloride) Tablet, Film Coated [AvKARE, Inc.]
Updated Date: Nov 5, 2014 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))
Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST) - November 5, 2014 Category: Drugs & Pharmacology Source Type: news

One million women denied 7p breast cancer drug that can halve chance of developing disease
One million women have been denied pills that could reduce chances of developing breast cancer. Tamoxifen, Raloxifene and Anastrozole have not been licensed for preventative use. (Source: the Mail online | Health)
Source: the Mail online | Health - September 29, 2014 Category: Consumer Health News Source Type: news

One million women denied the 7p breast cancer drug that can halve chance of developing disease because of red tape
One million women have been denied pills that could reduce chances of developing breast cancer. Tamoxifen, Raloxifene and Anastrozole have not been licensed for preventative use. (Source: the Mail online | Health)
Source: the Mail online | Health - September 29, 2014 Category: Consumer Health News Source Type: news

RALOXIFENE HYDROCHLORIDE Tablet [Camber Pharmaceuticals Inc]
Updated Date: Sep 25, 2014 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))
Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST) - September 25, 2014 Category: Drugs & Pharmacology Source Type: news

Review Examines Efficacy and Safety of Osteoporosis Drugs (FREE)
By Amy Orciari Herman Edited by David G. Fairchild, MD, MPH, and Jaye Elizabeth Hefner, MD Bisphosphonates, denosumab, teriparatide, and raloxifene all reduce risk for fracture relative to placebo in women with osteoporosis, according to a federally commissioned systematic review … (Source: Physician's First Watch current issue)
Source: Physician's First Watch current issue - September 9, 2014 Category: Primary Care Source Type: news

Revealing novel mode of action for osteoporosis drug
Raloxifene is a US Food and Drug Administration-approved treatment for decreasing fracture risk in osteoporosis. While raloxifene is as effective at reducing fracture risk as other current treatments, this works only partially by suppressing bone loss. X-ray studies revealed an additional mechanism underlying raloxifene action, providing an explanation for how this drug can achieve equivalent clinical benefit. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - August 29, 2014 Category: Science Source Type: news

Revealing a novel mode of action for an osteoporosis drug
(DOE/Argonne National Laboratory) Raloxifene is a US Food and Drug Administration-approved treatment for decreasing fracture risk in osteoporosis. While raloxifene is as effective at reducing fracture risk as other current treatments, this works only partially by suppressing bone loss. X-ray studies revealed an additional mechanism underlying raloxifene action, providing an explanation for how this drug can achieve equivalent clinical benefit. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - August 29, 2014 Category: Global & Universal Source Type: news

EVISTA (Raloxifene Hydrochloride) Tablet [Eli Lilly And Company]
Updated Date: Aug 6, 2014 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))
Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST) - August 6, 2014 Category: Drugs & Pharmacology Source Type: news

500,000 denied 7p-a-day breast cancer drug
Those with a family history of breast cancer should be offered Tamoxifen or the similar drug Raloxifene, which can cut their risk by 40 per cent. (Source: the Mail online | Health)
Source: the Mail online | Health - July 2, 2014 Category: Consumer Health News Source Type: news

RALOXIFENE HYDROCHLORIDE (Raloxifene Hydrochloride) Tablet [KAISER FOUNDATION HOSPITALS]
Updated Date: Jun 4, 2014 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))
Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST) - June 4, 2014 Category: Drugs & Pharmacology Source Type: news

Deirdre Connelly
President, North American Pharmaceuticals Deirdre Connelly joined GSK as President, North American Pharmaceuticals, on 9 February 2009.  She reports to Andrew Witty, Chief Executive Officer and is a member of GSK’s Corporate Executive Team. Prior to this, Deirdre was appointed President of US operations at Eli Lilly and Company in 2005.  Previously she was senior vice president for Human Resources for Lilly.  She had joined Lilly in 1983 as a sales representative and moved to San Juan as a marketing associate a year later.  After progressing through sales and marketing roles of increasing responsi...
Source: PHRMA - April 7, 2014 Category: Pharmaceuticals Authors: Julie Source Type: news

RALOXIFENE HYDROCHLORIDE Tablet, Film Coated [Teva Pharmaceuticals USA Inc]
Updated Date: Mar 31, 2014 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))
Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST) - March 31, 2014 Category: Drugs & Pharmacology Source Type: news

Teva's Generic Evista Approved In The U.S.
Teva announced that its generic equivalent to Evista (raloxifene) 60 mg tablets has been approved in the U.S. The approval makes Teva’s generic version eligible for 180 days of marketing exclusivity. (Source: Pharmaceutical Online News)
Source: Pharmaceutical Online News - March 10, 2014 Category: Pharmaceuticals Source Type: news

Teva Announces Approval of Generic Evista(R) Tablets 60 mg in the United States
JERUSALEM--(Healthcare Sales & Marketing Network)--Teva Pharmaceutical Industries Ltd. (TEVA) announces the approval of the generic equivalent to Evista® (Raloxifene) Tablets, 60 mg, in the United States. Teva was first to file, making the product elig... Biopharmaceuticals, Generics, FDA, Product LaunchTeva Pharmaceutical, Evista, Raloxifene (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - March 4, 2014 Category: Pharmaceuticals Source Type: news

RALOXIFENE HYDROCHLORIDE (Raloxifene Hydrochloride) Tablet [Prasco Laboratories ]
Updated Date: Mar 4, 2014 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))
Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST) - March 4, 2014 Category: Drugs & Pharmacology Source Type: news

Evista (Raloxifene HCI) Lowers Risk of Invasive...
Evista (raloxifene) is a drug that has been used for treatment of osteoporosis in postmenopausal women. The FDA has also approved it for prevention of invasive breast cancer. Evista creates an estrogen blockade, which lowers the incidence of estrogen-sensitive breast cancer. Learn more about Evista - uses, side effects, and benefits. (Source: About.com Breast Cancer)
Source: About.com Breast Cancer - February 21, 2014 Category: Cancer & Oncology Authors: breastcancer.guide at about.com Tags: health Source Type: news

Women who could benefit from medicine to prevent breast cancer often don't take them
Many new and potent medicines to prevent breast cancer have become available in the past 20 years. Surprisingly, many women—even those at high risk for the disease—are not taking advantage of these medicines, according to an article in the January 2014 issue of the Harvard Women's Health Watch. Drugs such as tamoxifen (Nolvadex), raloxifene (Evista), and exemestane (Aromasin) can reduce the odds of developing breast cancer for many women at high risk of developing breast cancer. "These drugs have been shown to prevent the occurrence of invasive and pre-invasive breast cancers," says Dr. Paul Goss, dir...
Source: New Harvard Health Information - December 20, 2013 Category: Consumer Health News Source Type: news

Anastrozole may cut breast cancer risk
Conclusion Overall, the study provides solid and believable evidence that anastrozole can reduce the number of new cases of breast cancer in postmenopausal women at higher than average risk of developing breast cancer. The study has many strengths, including its large sample size and robust study design. However, the study also has limitations to note. The results only apply to a specific group of postmenopausal women at a higher than average risk of developing breast cancer. "Higher risk" was defined using a number of very specific criteria. This means the results are not applicable to other groups of post...
Source: NHS News Feed - December 13, 2013 Category: Consumer Health News Tags: Cancer Medication Source Type: news

Breast cancer drug 'halves likelihood of high-risk women developing disease'
Anastrozole must be made available on NHS immediately, say charities and authors of trial funded by Cancer Research UKA drug not yet available on the NHS has been found to be better at preventing breast cancer than those approved for use, leading to urgent calls for the National Institute for Health and Care Excellence to make it accessible immediately.The drug anastrozole has been found to halve the likelihood of high-risk women developing the disease and to have fewer side-effects, according to a study published on Thursday in the Lancet medical journal. The Ibis-II study, funded by Cancer Research UK and led by Queen Ma...
Source: Guardian Unlimited Science - December 12, 2013 Category: Science Authors: Alexandra Topping Tags: theguardian.com News Health Society Drugs The National Institute for Health and Care Excellence (Nice) UK news Breast cancer NHS Science Source Type: news

Dr. Timothy J. Garnett
Chief Medical Officer & SVP, Eli Lilly & CompanyDr. Timothy Garnett, FRCOG, MFFP, FFPM, is Chief Medical Officer, Senior Vice-President and Co-Leader of the Development Center of Excellence managing Medical Affairs, Global Health Outcomes, Regulatory, Safety and Translational Medicine/Pharmacogenomics for Eli Lilly and Company. During his 14 years at Lilly, Dr. Garnett has served as Vice President for Global Patient Safety; Global Brand Development Leader and Group Medical Director responsible for the development of Duloxetine for incontinence, pain and depression; Medical Director Duloxetine SUI Team; and European...
Source: PHRMA - November 5, 2013 Category: Pharmaceuticals Authors: Leah Source Type: news